cd19 car-t + cd20 car-t + cd22 car-t + cd30 car-t

This therapy is a multi-targeted immunotherapy strategy consisting of a cocktail or sequential infusion of autologous T cells engineered to express chimeric antigen receptors (CARs) against four distinct B-cell and activation markers: CD19, CD20, CD22, and CD30. The primary objective of this quadruple-antigen approach is to minimize the risk of 'antigen escape,' a common resistance mechanism where tumor cells evade single-target CAR-T therapies (such as those targeting CD19 alone) by downregulating or losing the target protein. By targeting multiple antigens simultaneously or in sequence, the therapy aims to ensure more comprehensive eradication of the malignant B-cell population. This specific combination has been primarily investigated in clinical trials for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), where it seeks to improve the depth and durability of clinical responses compared to monotherapy.

Other names

CD19/CD20/CD22/CD30 CAR-T cocktailCD19, CD20, CD22 and CD30 CAR-T cells cocktailquad-targeted CAR-T cocktail